Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00597
Abstract: PURPOSE Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL,… read more here.
Keywords: cell; patients newly; rli; newly diagnosed ... See more keywords
Leveraging long-acting IL-15 agonists for intratumoral delivery and enhanced antimetastatic activity
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2024.1458145
Abstract: Introduction IL-15 agonists hold promise as immunotherapeutics due to their ability to induce the proliferation and expansion of cytotoxic immune cells including natural killer (NK) and CD8+ T cells. However, they generally have short half-lives… read more here.
Keywords: long acting; half life; acting agonists; rli ... See more keywords
Management and effects of residual limbus inversion following closed reduction in developmental hip dysplasia: Protocol for a multicenter randomized controlled trial
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.1072831
Abstract: Closed reduction is a common treatment method for developmental dysplasia of the hip (DDH) in children aged 6–18 months. Residual acetabular dysplasia (RAD) is the most common complication associated with closed reduction. Residual limbus inversion… read more here.
Keywords: ddh; limbus inversion; closed reduction; rli ... See more keywords